Neurocrine Biosciences' drug portfolio is turning a corner, and the company will soon be “knocking on the doors of the large-cap club,” according to Wells Fargo. Analyst Mohit Bansal upgraded the stock from equal-weight to overweight and raised his price target to $170 from $140, suggesting upside potential of around 21% from Tuesday's close. Bansal forecasts that the company's congenital adrenal hyperplasia treatment, crinecerfont, will reach $1.5 billion in peak sales, surpassing its previous estimate of $1.1 billion. “Crinecerfont alone is enough to justify a purchase,” Bansal wrote in a Tuesday note. “We think [the] crinecerfont [opportunity] is underrated as the Street only provides credit for maximum opportunities of $500 to $700 million.” Elsewhere in the company's portfolio, Neurocrine's depression drug NBI-1065845, developed in conjunction with Japanese pharmaceutical company Takeda , showed positive results during a Phase II trial. Bansal said this drug could open “a whole new chapter” of a $1.2 billion peak sales opportunity The NBI-'845 treatment could be “another blockbuster opportunity.” , Bansal said, citing the once-daily administration of the treatment as a factor in his assessment. Competing therapies are taken twice a day, he said. Shares are up nearly 6% in 2024. % in the last 12 months: CNBC's Michael Bloom contributed to this report.
More women who are not pregnant are requesting abortion pills just in case
Moderna Stock Rises After Oppenheimer Upgrade on Pipeline Potential
Should palliative psychiatry be considered for anorexia?
Sidney M. Wolfe, scourge of the pharmaceutical industry, dies at 86
Woman sues dentist after receiving 4 root canals, 8 crowns and 20 fillings in 1 visit